Efficacy of Ayush medicine NOQ19 in treatment of COVID-19 patients
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2022/01/039370
- Lead Sponsor
- Sriveda Sattva Private limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Hospitalized or in home isolation adult patient aged >18 years
Confirmed COVID-19 infection (RT ââ?¬â??PCR- Upper respiratory tract nasopharyngeal and oropharyngeal swab.
mild and moderate Symptomatic COVID 19 infection with or without comorbidities
Willingness to participate in the study
Indian nationals
Exclusion Criteria
Age less than 18 years
Pregnancy and Lactation
Moribund state in which death is perceived to be imminent (�48 hours)
Patient not willing to participate in the study
Participation in any other clinical study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effect of NF2 in COVID 19 patients as time to become COV2 RT-PCR negative, duration of hospital stay, time to resolution of symptomsTimepoint: 7 days for each participant
- Secondary Outcome Measures
Name Time Method Effect of NF2 therapy on laboratory parameters - CBC, CRP, LFT, KFTTimepoint: Entry and Exit